Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth ...

Medically reviewed by Danielle Weiss, MD Diabetic macular edema (DME) is a leading cause of vision loss in people with ...

Kodiak Sciences Inc. , today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "In September of 2024 we hosted an Investor R&D Day ...

The investigators conducted a prospective interventional study to determine the therapeutic anatomic and functional effects ...

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for ...

Vasan Eye Care continues to pave the way for better vision and overall improved quality of life for everyone ...

Blindness or vision loss is a growing concern among older adults, and one of the leading causes is a condition known as ...

Surrozen (SRZN) announced that the company will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ...

UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical ...

UBX] has announced top-line results from the Phase IIb ASPIRE clinical trial of intravitreal UBX1325 (foselutoclax) in ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...